Organ-sparing central pelvic compartment resection for the treatment of vulvo-vaginal melanomas.

IF 1 Q4 ONCOLOGY Melanoma Management Pub Date : 2024-01-12 eCollection Date: 2023-09-01 DOI:10.2217/mmt-2023-0001

Mark McGowan, Brent O'Carrigan, Filipe Correia Martins, Krishnayan Haldar, Pubudu Pathiraja

引用次数: 0

Abstract

Vulvo-vaginal melanomas are one of the rarest gynecological oncology diseases with a poor survival compared with other malignancies. The 5-year survival varies from 13% to 32.3%. Vulvo-vaginal melanomas involving the upper 2/3rds of the vagina are usually treated with total pelvic exenteration (TPE). TPE surgery carries a 50% risk of major complications and also morbidity associated with double stomas. Central pelvic compartment resection is a novel organ-sparing surgical approach entailing radical total laparoscopic hysterectomy, bilateral salpingo-oophrectomy, laparoscopic vaginectomy and vulvectomy to reduce morbidity compared with TPE. Permanent suprapubic catheters are used if there is urethral involvement but require quality of life studies to assess their long-term outcomes.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

治疗外阴阴道黑色素瘤的中央盆腔保留器官切除术。

外阴阴道黑色素瘤是最罕见的妇科肿瘤疾病之一，与其他恶性肿瘤相比，生存率较低。5 年生存率从 13% 到 32.3% 不等。累及阴道上2/3部分的外阴阴道黑色素瘤通常采用盆腔全切除术（TPE）治疗。TPE手术有50%发生重大并发症的风险，而且还存在与双腔相关的发病率。盆腔中央分隔切除术是一种新型的器官保留手术方法，包括根治性全腹腔镜子宫切除术、双侧输卵管切除术、腹腔镜阴道切除术和外阴切除术，与TPE相比，可降低发病率。如果尿道受累，则使用永久性耻骨上导尿管，但需要进行生活质量研究，以评估其长期效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.